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Objective: To examine restart of MTX treatment among patients with rheumatoid arthritis (RA) who discontinues
treatment, and investigate predictors of restart.
Methods: A cohort study was conducted based on data from medical databases. MTX drug discontinuation was
defined as a gap≥ 90 days from the expiration of one MTX prescription to the redemption of a new one. Kaplan Meier
estimates were used to compute the cumulative probability of restarting MTX treatment and Cox proportional hazard
to estimate the hazard of return to treatment. A case-crossover analysis compared the frequency of events that could
potentially have a transient effect on MTX restart.
Results: Among 788 patients, who started MTX, 299 patients experienced a gap≥ 90 days. Within 1.4 years 50 % of
these patients returned to treatment, and a total of 66 % restarted treatment during follow-up. Concurrent treatment
with corticosteroid and disease-modifying antirheumatic drugs (DMARDs) tended to be negatively associated with MTX
restart (OR: 0.7(95 % CI: 0.5-1.2) and (OR: 0.7 (95 % CI: 0.4-1.0)). Older patients were less inclined to restart treatment than
middle-aged patients (Adjustet HR 0.7 (0.4-1.2)). Patients with a CRP > 300 nmol/L less often restarted MTX than patients
with a CRP < 75 nmol/L (adjHR: 0.6 (95 % CI 0.3-1.2)), and men were more inclined to MTX restart than women (adjHR
1.30 (95 % CI 0.9-2.0)).
Conclusion: It is important to support patients in remaining continuous users of MTX. A large proportion of RA
patients who discontinued MTX later restarted treatment, but especially patients with high disease activity, old
age or co-morbidity were less inclined to restart treatment.
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In rheumatoid arthritis (RA) methotrexate (MTX) is still
considered the first drug of choice and early, aggressive
and continuous treatment is recommended (Royal College
of Physicians 2009; Lopez-Olivo et al. 2014). Sequencing
of DMARD has recently been investigated in a systematic
review among 503 RA patients in stable disease who were
randomized to either continuous treatment or placebo. It
was found that patients who remained on effective* Correspondence: annethur@rm.dk
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medium, provided the original work is properlyDMARD had significantly fewer flare episodes than those
who discontinued treatment (O’Mahony et al. 2010).
Newly, the effectiveness of MTX was once again verified
in a meta-analysis (Lopez-Olivo et al. 2014). The same
study showed that the MTX discontinuation rate due to
adverse effects within 52 weeks were 16 %. In an earlier
register based study about MTX compliance we went
through a total of 509 medical journals to look for reasons
for MTX discontinuation. In this sample approximately
30 % of the patients discontinued MTX at any time during
follow-up, and 50 % of this discontinuation were explained
by adverse events (AE). The most frequent reported AE
was gastrointestinal symptoms (30 %) (de Thurah et al.
2010). It is known, that in chronic diseases such asarticle distributed under the terms of the Creative Commons Attribution
y/4.0), which permits unrestricted use, distribution, and reproduction in any
credited.
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restart treatment for different reasons (Harrold et al. 2010;
Brookhart et al. 2007), but it is unclear whether RA pa-
tients likewise tend to stop and restart MTX treatment.
In this study we wish to describe the extent to which
RA patients, who discontinued MTX treatment for an
extensive period, later resumed their treatment and fur-
ther, to investigate whether clinically important factors
such as disease duration, disease activity and side effects
could predict return to MTX treatment.
Methods
Study population
The study was conducted in the County of Aarhus,
Denmark, with a population of approximately 650,000 in-
habitants, corresponding to 13 % of the Danish population.
We identified patients with RA through the Danish
National Patient Registry (DNPR) using the following
ICD-10 codes: M05.3, M05.9, M05.8, M06.0 and M06.9.
Our analysis focused on new users of MTX defined as pa-
tients with at least one prescription of MTX redeemed
between 1 January 1998 and 31 December 2006 and no
prescription for MTX redeemed in 1996 and 1997. We
retrieved information on MTX use from the regional
Pharmaco-Epidemiological Prescription Database (PEPD).
All pharmacies in Denmark are equipped with electronic
accounting systems that are used to secure reimbursement
from the National Health Service, which funds a variable
proportion of the cost of prescribed medicine for all Danish
citizens. Data are transferred to the PEPD, which thus
covers all reimbursed drugs at the level of the individual
user. The database includes: 1) information on type of drug
according to the Anatomical Therapeutical Chemical Clas-
sification System (ATC), 2) the date when the prescription
was filled, 3) the patients civil registry number (CPR num-
ber), 4) packing size and the number of pills in each pack-
age (always 100 tablets of 2.5-mg), and 5) the amount of
drug according to number of defined daily doses (DDD)
(WHO 2015). The ATC codes for MTX are: L01BA01 and
L04AX03 (WHO 2015). In Denmark the physicians and
pharmacists are regulated separately which means a separ-
ation of prescribing and dispensing of drugs. Hence, the
pharmacists must give the exact treatment prescribed by
the doctor. Only oral MTX is included in the PEDP.
Definition of treatment gaps and return to treatment
No standard definition exist on the length of a gap that
qualifies as drug discontinuation based on pharmacy re-
cords. Our definition is based on the literature saying
that the variation in persistence is most pronounced for
treatment gaps between 9–90 days, whereas treatment
gaps between 90–360 days only have minor influence on
the percentage of persistent patients (Van Wijk et al. 2006).
Thus, in conjunction with others (Grijalva et al. 2007), wedefined MTX drug discontinuation as a gap ≥ 90 days from
the expiration of one MTX prescription to the redemption
of a new one. We accordingly defined return to treat-
ment as redemption of an MTX prescription after a
gap ≥ 90 days.
As the PEPD does not contain data on the exact doses,
but only the defined daily dose (DDD), we reviewed the
medical records of all patients and retrieved the pre-
scribed daily dose (PDD) defined as the dose the patients
were receiving 6 months after stat of treatment (Steiner
& Prochazka 1997). The PDD was used in the calcula-
tion of the gabs, and the 90-days gab in treatment could
occur at any time during follow-up.
Other covariates
We defined disease duration as the time from the date
of first RA diagnosis in the NPR until the date of the
first MTX prescription in the PEPD.
From the County Clinical Biochemistry Registry we
retrieved the latest C-reactive protein (CRP), alanine
aminotransferase (ALAT) and hemoglobin (Hb) analysis
performed prior to a gap ≥ 90 days. We regarded CRP as
surrogate marker for disease severity (Yildirim et al.
2004). We defined liver enzyme evaluation as ALAT two
times the upper limit of normal (Saag et al. 2008). Low
hemoglobin was defined as: female: < 7.4 mmol/l, male:
< 8.4 mmol/l.
Co-morbidity was assessed by Charlsons Co-morbidity
Index (CCI) (Charlson et al. 1987) and patients were cate-
gorized as having co-morbidity if, since 1997, they had at
least one of the 19 CCI diagnoses recorded in the NRP.
Through the PEPD we retrieved information on concur-
rent use of corticosteroids (H02AB06) and other conven-
tional DMARDs: sulfasalazine (A07EC01) and cloroquine
(P01BA0, P01BA01).
In Denmark, biological DMARDs are managed through
hospital and thus are not a part of the PEDP. We collected
data on Etanercept (ATC L04AA11), Infliximab (ATC
L04AA12) and Adalimumab (ATC L04AA17) through the
Danish Danbio register (Hetland et al. 2005). However, as
most patients switched to subcutanous MTX treatment
before initiating anti-TNF-alfa treatment to few cases were
left for analysis. Leflunmide, goldsalt, penicillamin and
cyclosporine are very seldom used in RA in Denmark.
Statistics
Included patients were followed from the date they experi-
enced a first gap, until a new prescription was filled or the
end of the study period, whichever came first. Kaplan
Meier estimates were used to estimate the cumulative
probability of MTX restart, and Cox proportional hazard
to estimate the hazard ratio of restart. Case-crossover ana-
lysis was used to compare the frequency of factors with
potential effect on MTX restart (CRP, hemoglobin, ALAT,
Fig. 1 1-Kaplan Meier estimate of the cumulative probability of returning to Methotrexate treatment after a gap≥ 90 days among 299 rheumatoid
arthritis patients in the County of Aarhus, Denmark 1996–2006
de Thurah et al. SpringerPlus  (2015) 4:227 Page 3 of 5concurrent use of conventional DMARDs and corticoste-
roids). The frequency was estimated within 60 days before
MTX restart (the hazard period) and compared with the
frequency 61–180 days before MTX restart (the control
period) (Schneeweiss et al. 1997).Table 1 Crude and adjusted hazard ratios (HR) with 95 %
confidence interval (CI) for methotrexate restart after a
treatment gab ≥ 90 days among 299 patients with
rheumatoid arthritis in the County of Aarhus, Denmark
1998-2006
Gender Male 203 (67.9) 1.3 (0.9;1.9) 1.3 (0.9;2.0)
Female 96 (32.1) 1 1
Age <55 years 109 (36.5) 0.8 (0.5;1.3) 0.9 (0.6;1.7)
55-67 years 92 (30.7) 1 1
>67 years 98 (32.8) 0.7 (0.4;1.1) 0.7 (0.4;1.2)
C-reactive
protein
< 75 nmol/L 154 (51.5) 1 1
76-300 nmol/L 78 (26.1) 1.0 (0.6;1.5) 1.1(0.7;1.8)
>300 nmol/L 60 (20.1) 0.5 (0.3;0.9) 0.6 (0.3;1.2)
Missing 7 (2.3) - -
Hemoglobin Low 89 (29.8) 1.4 (0.9;2.2) 1.0 (0.6;1.8)
Normal 203 (67.9) 1 1
Missing 7 (2.3) - -
Co-morbidity 0 209 (69.9) 1 1
> = 1 90 (30.1) 0.8 (0.5;1.2) 0.8 (0.5;1.3)
Concurrent
DMARD
Yes 110 (36.8) 0.7 (0.5;1.0) 0.8 (0.5; 1.2)
No 189 (63.2) 1 1
Corticosteroids Yes 100 (33.4) 0.5 (0.3,0.7) 0.7 (0.4;1.1)
No 189 (66.6) 1 1Results
During the study period 788 patients started MTX treat-
ment and 299 patients (38 %) experienced a gap ≥ 90 days.
These patients were followed for a median of 352 days
(range 168–2067) from 90 days after their last MTX pre-
scription had expired (Fig. 1).
The percentage of younger patients (<55 years) who ex-
perienced a treatment gap was 36 % vs. 28 % among those
who did not. Patients with and without a gab had similar
distribution of sex, co-morbidity, disease duration, concur-
rent medication, and disease activity.
Within 1.4 years 50 % of the patients restarted MTX,
and within 3 years 66 % of the patients had restarted
treatment (Fig. 1). None of the factors in the case-cross
over analysis were associated with MTX restart. Only con-
current treatment with either corticosteroid or DMARDs,
showed a tendency towards a negative association to MTX
restart (OR 0.7 (95%CI 0.4;1.1) and OR 0.7 (95 % CI.0.4;1.2)
respectively) (Table 1).
Data suggested that older patients less often restarted
MTX treatment compared with middle-aged patients
(adjusted hazard ratio (adjHR): 0.7 (95 % confidence inter-
val (CI) 0.4-1.2)). A similar pattern was seen for patients
with co-morbidities compared with patients without co-
morbidity (adjHR: 0.8 (95 % CI 0.5-1.2)). Patients with a
CRP > 300 nmol/L less often restarted MTX than patients
with a CRP < 75 nmol/L (adjHR: 0.6 (95 % CI 0.3-1.2)),
and men were more inclined to MTX restart than women(adjHR 1.30 (95 % CI 0.9-2.0)). However, none of the pre-
dictors reached statistical significance (Table 1).
Discussion
The present study found that among RA patients who
discontinued MTX treatment ≥ 90 days, 66 % restarted
treatment within 3 years of follow-up, suggesting MTX
utilization among RA patients to resemble medication-
de Thurah et al. SpringerPlus  (2015) 4:227 Page 4 of 5taking patterns in line with that seen among patients with
other chronic diseases (Harrold et al. 2010; Brookhart
et al. 2007).
In daily clinical practise, an inadequate response to
MTX may be followed by switching to an alternative
DMARD (Royal College of Physicians 2009), and in line
with this we found the use of either corticosteroids or
concurrent DMARDs to deter MTX restart. Similar to
others, (Schmajuk et al. 2010; Solomon et al. 2014) we
also found that patients with increasing age and high
levels of co-morbidity were less prone to restart MTX
treatment. In a previous study about MTX compliance
among patients with RA we found men to be more com-
pliant compared to women (de Thurah et al. 2010). In
keeping with this finding the current study also found
men to be more inclined to MTX restart than women.
The present study has limitations that merit further
discussion.
First of all, it is a challenge to determine the length of
the gap that defines drug discontinuation, and no standard
definition exists (Steiner & Prochazka 1997). However, a
Dutch cohort study investigating the variation in persist-
ence with drugs found that the variation in persistence
was most pronounced for treatment gaps between 9–90
days, whereas treatment gaps between 90–360 days only
had minor influence on the percentage of persistent pa-
tients (Van Wijk et al. 2006). Hence, we choose ≥ 90 days
as cut off in the definition of a treatment gab.
Secondly, we lacked data on level of pain and functional
disability that could potentially have influenced MTX
utilization more directly and further, we were unable to
determine whether gaps in MTX treatment were doctor
prescribed, i.e. due to side effects (Nikiphorou et al. 2014).
In an earlier register based study about MTX compliance
we went through a total of 509 medical journals to look
for reasons to MTX discontinuation (de Thurah et al.
2010). In this sample approximately 30 % of the patients
discontinued MTX at any time during follow-up, and
50 % of this discontinuation were explained by AE’s. The
most frequent reported AE was gastrointestinal symptoms
(30 %). In general, the documentation of data in this area
tend to be insufficient in the medical records, potentially
leading to differential misclassification, as reasons for doc-
tor prescribed or, especially, patient initiated breaks are
only sporadic documented. In a recent meta-analysis MTX
discontinuation rate due to AE’s within 52 weeks were
found to be 16 % (Lopez-Olivo et al. 2014), and our find-
ing, that toxicity rather than lack of effect were the main
reason for MTX discontinuation is in agreement with this
observation (Felson et al. 1992).
In conclusion, our findings suggest that RA patients
frequently stop and restart treatment. We found that es-
pecially patients with high disease activity and old age or
co-morbidity were less inclined to restart treatment.Hence, addressing MTX utilization and side effects rou-
tinely is important in daily clinical practise in order to
help patients to remain continuous users.
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